142 related articles for article (PubMed ID: 19254348)
1. The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
Lü S; Chen Z; Yang J; Chen L; Zhou H; Xu X; Li J; Han F; Wang J
Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e123-31. PubMed ID: 19254348
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
Zheng B; Zhou R; Gong Y; Yang X; Shan Q
Int J Lab Hematol; 2012 Jun; 34(3):237-47. PubMed ID: 22145750
[TBL] [Abstract][Full Text] [Related]
3. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells.
Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ
Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047
[TBL] [Abstract][Full Text] [Related]
4. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Minderman H; Zhou Y; O'Loughlin KL; Baer MR
Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
[TBL] [Abstract][Full Text] [Related]
6. [Effect of proteasome inhibitor bortezomib on proliferation, apoptosis and XIAP expression in K562 cells].
Shao M; Sun L; Cui XY; Han XF; Chen SM; Wang F; Zhang H; Ling Z
Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):182-6. PubMed ID: 21535957
[TBL] [Abstract][Full Text] [Related]
7. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
8. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors.
Rumpold H; Salvador C; Wolf AM; Tilg H; Gastl G; Wolf D
Biochem Biophys Res Commun; 2007 Sep; 361(2):549-54. PubMed ID: 17662692
[TBL] [Abstract][Full Text] [Related]
10. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.
Li YC; Wang HH; Liao AJ; Fu BB; Zhang R; Li J; Yang Y; Liu ZG; Yang W
Eur Rev Med Pharmacol Sci; 2014; 18(10):1465-72. PubMed ID: 24899604
[TBL] [Abstract][Full Text] [Related]
12. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
13. [Effects of tetrandrine on nuclear factor-kappaB expression in leukemia multidrug-resistant cell line K562/A02].
Chen BA; Su AL; Cheng J; Zhao HH; Li GH; Wang XM
Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):956-9. PubMed ID: 18782542
[TBL] [Abstract][Full Text] [Related]
14. [Reversal of multi-drug resistance in K562/A02 cells by small interference RNA of mdr1 gene].
Peng Z; Xiao ZJ; Wang Y; Liu P; Cai YL; Feng WL; Han ZC
Zhonghua Xue Ye Xue Za Zhi; 2004 Jan; 25(1):5-7. PubMed ID: 14990067
[TBL] [Abstract][Full Text] [Related]
15. Induction of actin disruption and downregulation of P-glycoprotein expression by solamargine in multidrug-resistant K562/A02 cells.
Li X; Zhao Y; Ji M; Liu SS; Cui M; Lou HX
Chin Med J (Engl); 2011 Jul; 124(13):2038-44. PubMed ID: 22088467
[TBL] [Abstract][Full Text] [Related]
16. [Effect of tetrandrine and droloxifene on the reversion of drug resistance of K562/A02 cell line and induction of apoptosis].
Chen B; Dong Y; Zhang P; Cheng J; Zhou Y; Sheng M; Wang T; Gao F
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):526-8. PubMed ID: 12667316
[TBL] [Abstract][Full Text] [Related]
17. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
[TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
20. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
